Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

about

Cancer stem cell signaling pathways.Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.Management of myelofibrosis: JAK inhibition and beyond.

P2860

Q38950221-BD447456-5BBE-460C-86F6-21BC14D22ADF Q39125504-60FA4CC5-3C24-4203-9679-6CC6CABDBCC6 Q39232415-5E570E8F-E8A0-478D-AFAC-B6D49DA25CDD

P2860

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

Item

http://www.wikidata.org/entity/Q43122604

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@en

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@nl

type

Item

label

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@en

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@nl

prefLabel

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@en

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@nl

P1476

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

@en

P2093

Carlos Magno da Costa Maranduba

http://www.w3.org/2001/XMLSchema#string

Renata Mendes de Freitas

http://www.w3.org/2001/XMLSchema#string

P2860

The Janus kinases (Jaks)

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers

JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Chronic myeloproliferative disorders

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

P304

348-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BJHH.2014.10.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278333823

http://www.w3.org/2001/XMLSchema#string

P698

26408371

http://www.w3.org/2001/XMLSchema#string

P932

4685044

http://www.w3.org/2001/XMLSchema#string

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

about

P2860

P2860

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932